For years, families of young children with plaque psoriasis faced a frustrating situation: the creams most often prescribed for their kids came with strings attached. Steroid creams—a common treatment for this itchy, scaly skin condition—cannot safely be used on sensitive areas like the face or skin folds, and doctors caution against using them for long periods. But now, there's a new option for America's youngest psoriasis patients.
The U.S. Food and Drug Administration has approved Zoryve (roflumilast) cream for children as young as 2 years old who have plaque psoriasis. The drug, made by Arcutis Biotherapeutics, is a once-daily topical cream—meaning it's applied directly to the skin—that contains no steroids and carries no time limits on how long it can be used.
The approval applies to patients ages 2 and older across the United States and covers treatment anywhere on the body, including those tricky spots like the eyelids, face, and areas where skin folds against skin.
Dr. Lisa Swanson, a dermatologist who helped test the drug in clinical trials, explained why this matters so much for little ones. "Young children with plaque psoriasis face unique challenges, including disease involvement on sensitive skin, such as the face and skin folds," she said in a statement. "Although topical steroids are commonly used to treat pediatric plaque psoriasis, they are not recommended on sensitive areas or for long-term, continuous use."
The FDA based its decision on research that followed young children ages 2 to 5 with psoriasis affecting at least 2 percent of their body surface area. In a four-week study, researchers checked how the children's bodies absorbed the medication, along with its safety and how well it worked. Additional safety data came from a follow-up study lasting up to 24 weeks. Both studies showed results that matched what researchers had already seen in older children, teens, and adults.
Zoryve belongs to a class of drugs called PDE4 inhibitors. Unlike steroid creams, it can be applied to delicate areas without the same risks, making it a gentler option for children whose skin is still developing.
For families dealing with the daily reality of childhood psoriasis—the itching, the discomfort, the self-consciousness—this approval opens a door that was previously closed.